Results 81 to 90 of about 2,062,013 (251)

Mesenchymal Stem Cells: A Trump Card for the Treatment of Diabetes?

Biomedicines, 2020
The advent of the new revolutionary approach based on regenerative medicine is progressively reshaping the therapeutic scenario of many different diseases, such as cardiovascular diseases and immune diseases, with encouraging results.
Elisabetta Donzelli, Arianna Scuteri
doaj   +1 more source

Poor baseline immune function predicts an incomplete immune response to combination antiretroviral treatment despite sustained viral suppression

, 2009
Objectives: To determine the prevalence and predictors of an incomplete immune response in patients with sustained viral suppression after starting their first or second combination antiretroviral treatment (cART) regimen.
Cooper, D.A., Kelly, Mark, Falster, Kathleen, Petoumenos, Kathy, Mijch, A., Petoumenos, K., A. Cooper, David, Kelly, M., Mijch, Anne, Chuah, John, Falster, K., Mulhall, B., Mulhall, Brian, Chuah, J., Mallal, S.   +14 more
core   +1 more source

Supplementary Figure from Entinostat Decreases Immune Suppression to Promote Antitumor Responses in a HER2⁺ Breast Tumor Microenvironment

, 2022
Supplementary Figure from Entinostat Decreases Immune Suppression to Promote Antitumor Responses in a HER2+ Breast Tumor ...
Elizabeth M. Jaffee (14960445), Julie K. Jang (14991383), Emily F. Davis-Marcisak (15129345), Anuj Gupta (4328764), Gaurav Sharma (749390), Luciane T. Kagohara (15129354), Sathish Kumar Ganesan (15109915), Evanthia T. Roussos Torres (15035010), Valerie H. Narumi (15129342), Sofi Castanon (15129333), Vered Stearns (15129348), Emma Bigelow (10799652), Min Yu (120607), Ajay Vaghasia (15099663), Alyza Skaist (6741407), Christine I. Rafie (15129330), Aaron G. Baugh (15129336), Edgar Gonzalez (15129339), Elana J. Fertig (8609136), Dimitrios N. Sidiropoulos (8812874), Roisin M. Connolly (15129351), Sarah J. Wheelan (15099675), Brian J. Christmas (15115141), Daria A. Gaykalova (8569809), Michael Considine (5269832), Srinivasan Yegnasubramanian (27577)   +25 more
core   +1 more source

Developmental programmes drive cellular plasticity, disease progression and therapy resistance in lung adenocarcinoma

Molecular Oncology, EarlyView.
This study shows that lung adenocarcinomas exploit developmental branching morphogenesis to acquire a therapy resistant basal‐like tumour cell state. This process was found to be regulated by combined TP53 loss‐of‐function and type‐I interferon signalling, identifying a novel axis for biomarker and therapeutic target discovery.
Kamila J Bienkowska, Stephany Gallardo, Nur S. Zainal, Leena Arora, Matthew Ellis, Maria‐Antoinette Lopez, Judith Austine, Sai Pittla, Serena J Chee, Aiman Alzetani, Emily C Shaw, Christian H Ottensmeier, Gareth J Thomas, Christopher J Hanley   +13 more
wiley   +1 more source

Psychophysical evidence for two routes to suppression before binocular summation of signals in human vision [PDF]

, 2007
Visual mechanisms in primary visual cortex are suppressed by the superposition of gratings perpendicular to their preferred orientations. A clear picture of this process is needed to (i) inform functional architecture of image-processing models, (ii ...
Baker, D.H., Summers, Robert J., Meese, T.S., Summers, R J, Meese, Timothy S., Summers, R.J., Baker, D H, Meese, T S, Baker, Daniel H.   +8 more
core   +1 more source

Nonlinear Within-Host Modeling of HBV Infection Reveals Immune-Dependent Clearance and Persistence Pathways

Complexity
We present a comprehensive within-host mathematical model to quantify long-term hepatitis B virus (HBV) dynamics under pharmacological immune suppression and subsequent immune recovery.
Malik Muhammad Ibrahim, Jihwan Ha, Muhammad Umair Ali, Yong Dam Jeong, Lijiao Jia, Kwang Su Kim   +5 more
doaj   +1 more source

Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr‐mutated lung cancer

Molecular Oncology, EarlyView.
Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura, Tadahiro Kuribayashi, Johannes Brägelmann, Sachi Okawa, Masataka Taoka, Shunta Mori, Tomoka Nishimura, Takaaki Tanaka, Go Makimoto, Kiichiro Ninomiya, Kammei Rai, Eiki Ichihara, Ryohei Katayama, Katsuyuki Hotta, Masahiro Tabata, Yosuke Togashi, Yoshinobu Maeda, Martin L. Sos, Katsuyuki Kiura, Kadoaki Ohashi   +19 more
wiley   +1 more source

USP29‐regulated noncanonical stabilization of the hypoxia‐inducible factor‐α in aggressive prostate cancer

Molecular Oncology, EarlyView.
We identify USP29 as the only DUB mirroring CA9 expression, a marker of hypoxia and HIF pathway activation associated with PCA aggressiveness. USP29 stabilizes HIF‐1α and HIF‐2α via a noncanonical mechanism that is independent of PHD/pVHL activity yet relies on proteasomal regulation, establishing USP29 as a previously unrecognized regulator of hypoxic
Amelie S Schober, Leire Moreno‐Cugnon, Laura Martínez‐Pérez, Amaia Ercilla, Amaia Zabala‐Letona, Adrián Vicente‐Barrueco, Maider Fagoaga‐Eugui, Saioa Garcia‐Longarte, Blanca Calle‐Ciborro, Encarnación Pérez‐Andrés, Onintza Carlevaris, Sara Pozo, Isabel Mendizabal, Ugo Mayor, Arkaitz Carracedo, Violaine Sée, Edurne Berra   +16 more
wiley   +1 more source

A novel quinazolinone insulin receptor inhibitor and its synergy with an EGFR inhibitor in glucose‐driven glioblastoma

Molecular Oncology, EarlyView.
The novel styrylquinazolinone‐based molecule W1B effectively suppresses glioblastoma by inhibiting IGF1R and EGFR. In high‐glucose microenvironments driving tumor resistance, W1B acts synergistically with the EGFR inhibitor dacomitinib. This combination safely blocks compensatory survival signaling in zebrafish xenograft models. Showcasing promising in
Patryk Rurka, Wioleta Cieślik, Wojciech Płaziński, Katarzyna Stępnik, Anna Boguszewska‐Czubara, Elżbieta Kot, Robert Musioł, Mateusz Jasica, Anna Mrozek‐Wilczkiewicz, Katarzyna Malarz   +9 more
wiley   +1 more source

Immunity and immune suppression in human ovarian cancer

, 2011
Clinical outcomes in ovarian cancer are heterogeneous, independent of common features such as stage, response to therapy and grade. This disparity in outcomes warrants further exploration into tumor and host characteristics.
Kimberly R Kalli, Ellen L Goode, Claudia C Preston, Lynn C Hartmann, Keith L Knutson   +4 more
core   +1 more source